netFormulary NHS
Nottinghamshire Area Prescribing Committee
Joint Formulary
 Search
 Results

Looking for Docetaxel found 19 matches

Formulary items 10 matches
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Docetaxel  (Taxotere) Malignant disease and immunosuppression - Taxanes - 08.01.05
  Restricted Drug Abiraterone  (Zytiga) Malignant disease and immunosuppression - Anti-androgens - 08.03.04.02
  Cytotoxic Drug Restricted Drug Cabazitaxel  (Jevtana) Malignant disease and immunosuppression - Taxanes - 08.01.05
  Restricted Drug Enzalutamide  (Xtandi) Malignant disease and immunosuppression - Anti-androgens - 08.03.04.02
  Restricted Drug Nintedanib  (Vargatef) Respiratory system - Antifibrotics - 03.11
  Cytotoxic Drug Restricted Drug Pertuzumab  (Perjeta) Malignant disease and immunosuppression - Trastuzumab - 08.01.05
  Restricted Drug Radium-223 dichloride
(Xofigo)
Malignant disease and immunosuppression - Prostate cancer and gonadorelin analogues - 08.03.04.02
  Cytotoxic Drug Trastuzumab  (Herceptin)
(Intravenous)
Malignant disease and immunosuppression - Trastuzumab - 08.01.05
  Cytotoxic Drug Restricted Drug Trastuzumab  (Herceptin)
(Subcutaneous)
Malignant disease and immunosuppression - Trastuzumab - 08.01.05
  Cytotoxic Drug Restricted Drug Trastuzumab  (Ontruzant)
(IV Biosimilar)
Malignant disease and immunosuppression - Trastuzumab - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA101: Prostate cancer (hormone-refractory) - docetaxel (08.01.05)
link in drug section NICE TA101: Prostate cancer (hormone-refractory) - docetaxel (08.01.05)
link in drug section NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (08.01.05)
link in drug section NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (08.01.05)
link in drug section NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (08.01.05)
link in drug section NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (08.01.05)
link in drug section NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (08.01.05)
link in drug section NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (08.01.05)
link in drug section SFH: Nintedanib and Docetaxel in NSCLC (03.11)


 

netFormulary